# Insulin Resistance in PCOS on GLP-1 Drugs: A Four-Trial Meta-Analysis | This GLP A meta-analysis of four randomized trials in PCOS found significant falls in waist, BMI and testosterone, and no significant change in HOMA-IR. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-pcos-insulin-resistance Updated: 2026-10-26 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Insulin Resistance in PCOS on GLP-1 Drugs: A Four-Trial Meta-Analysis Pooled across four small trials in PCOS, waist, BMI and testosterone fell. Insulin resistance, the reason these drugs are supposed to help, did not. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Pooled across four trials, 176 participants · waist circumference · −5.16 cm · BMI · −2.42 · triglycerides · −0.20 · total testosterone · −1.33 · total cholesterol · no difference · HOMA-IR · no difference **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Four randomized trials, 176 participants in total, pooled for women with PCOS and obesity. - Waist circumference fell 5.16 cm (95% CI −6.11 to −4.21) and BMI 2.42 points (−3.10 to −1.74). - Total testosterone fell by 1.33 (95% CI −2.55 to −0.12, p=0.03) and triglycerides by 0.20. - Total cholesterol did not move significantly, and neither did HOMA-IR (−0.30, 95% CI −0.92 to 0.32, p=0.35). - HOMA-IR is the marker closest to the reason these drugs are supposed to help PCOS. Polycystic ovary syndrome is tangled up with insulin resistance, and that is the usual explanation for why a drug like this should help — the same kind of mechanism story that [gets told about other hormonal conditions](https://thisglp.com/research/do-glp1-drugs-work-in-menopause). The pooled trial evidence supports part of it and not the part everyone names. ## What exists A meta-analysis searched four databases for randomized trials of a GLP-1 against placebo in women diagnosed with PCOS by the Rotterdam criteria, and found four. [\[1\]](https://thisglp.com/research/glp1-pcos-insulin-resistance#ref-1) Together they contributed 176 participants — not per arm, in total. Liraglutide accounted for 103 of them, 58 percent, and semaglutide for 23, or 13 percent. That composition matters before any result. Most of what is known here comes from a drug that is not what most people are prescribed now, in a pooled sample smaller than a single modest trial. ## What moved Waist circumference fell by 5.16 cm, 95% CI −6.11 to −4.21, p<0.00001. BMI fell 2.42 points, 95% CI −3.10 to −1.74. Serum triglycerides fell 0.20, 95% CI −0.30 to −0.11. Total testosterone fell by 1.33, 95% CI −2.55 to −0.12, p=0.03 — a real result whose interval comes close to zero. Adverse event information was available for 112 patients, of whom 49 reported light side effects such as nausea and abdominal pain. ## What did not Total cholesterol showed no significant difference, at −0.04, 95% CI −0.10 to 0.01, p=0.15. Neither did HOMA-IR, at −0.30, 95% CI −0.92 to 0.32, p=0.35. The null is on the mechanism HOMA-IR estimates insulin resistance, and insulin resistance is the reason usually given for why these drugs ought to treat PCOS rather than merely reduce weight in women who have it. It did not move significantly here. Meanwhile waist, BMI and triglycerides — the things a GLP-1 improves in almost anybody — did. On this evidence the effect looks general rather than PCOS-specific, and the honest summary says so. ## How much weight to give a null this small Not much, in either direction. With 176 people across four trials, a real moderate effect on HOMA-IR could easily go undetected. The interval runs from −0.92 to 0.32, which is wide enough to contain a meaningful improvement and a slight worsening at once. So the correct reading is not that these drugs fail to address insulin resistance in PCOS. It is that nobody has shown they do, on a sample this size, and that the results being quoted as evidence for PCOS treatment are mostly results about weight. That distinction is the same one that separates [a famous trial from a thin literature](https://thisglp.com/research/glp1-in-children-all-eighteen-trials) in other corners of this field. ## The testosterone question Hyperandrogenism is what many women with PCOS most want treated — the hair, the skin, the cycles. Total testosterone did fall, significantly. But the pooled estimate is a single laboratory number whose interval nearly reaches zero, drawn from four small trials, and no clinical outcome was pooled alongside it. Whether that translates into anything a person would notice is a different endpoint, and [which endpoint a study chose](https://thisglp.com/research/do-glp1-drugs-cause-gout) decides what it can tell you. ## What this means before ordering No seller on this roster offers a PCOS service or claims the indication. What is being sold is weight loss, and weight loss genuinely helps many PCOS symptoms — that is not in dispute and does not require this literature. What would be misleading is a purchase made on the belief that the drug is treating the underlying endocrinology. Four trials and 176 women do not establish that, and the marker closest to the claim is the one that did not move. PCOS care is a gynecologist or endocrinologist’s territory, and [the questions a seller leaves unanswered](https://thisglp.com/tools/questions-they-leave-open) include every one that matters here. [Allara Health](https://thisglp.com/reviews/allara-health) describes care for PCOS and insulin resistance on its [website](https://www.allarahealth.com/). That is a relevant practice scope to compare. It does not establish that a GLP-1 is the right treatment for every patient with PCOS. Ask which evaluation and ongoing care your plan includes. ## Frequently asked Do these drugs treat PCOS? They reduce weight, waist and BMI in women with PCOS, which helps many symptoms. The pooled evidence does not show a significant effect on insulin resistance, which is the mechanism usually invoked for a PCOS-specific benefit. How much evidence is there? Four randomized trials contributing 176 participants in total. Liraglutide accounts for 58% of them and semaglutide for 13%. Does testosterone come down? Total testosterone fell by 1.33 with a 95% CI of −2.55 to −0.12 and p=0.03. That is a laboratory result from four small trials, and no clinical outcome such as hair or cycle regularity was pooled alongside it. Can I buy one for PCOS here? No seller on this roster offers a PCOS service or claims the indication. What is sold is weight loss. ## Sources 1. \[1\] Austregésilo de Athayde De Hollanda Morais B, et al. (2024). The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: A meta-analysis of randomized controlled trials Journal of Diabetes and Its Complications. [PMID 39178623](https://pubmed.ncbi.nlm.nih.gov/39178623/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)